Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
复制标题
DOI：
10.1016/s0304-3940(01)01586-5
复制
发表时间：
2001-03-16
影响因子：
2.5
通讯作者：
Hesse, C
中科院分区：
文献类型：
--
作者：
Davidsson, P;Blennow, K;Hesse, C
通过测定脑脊液（CSF）中乙酰胆碱酯酶（AChE）的含量，评价阿尔茨海默病（AD）患者的临床意义及药物治疗效果。与对照组相比，AD患者的CSF-AChE较低，但不显著。然而，在使用AChE抑制剂（多奈哌齐和加兰他明）治疗AD患者后，CSF-AChE明显增加。用多奈哌治疗的患者比用加兰他敏治疗的患者增加得更高，这可能与两种物质的作用机制不同有关。这种增加也是剂量依赖性的，在表现出临床反应的患者中尤其明显。这些数据表明，脑脊液生物标志物不仅能够识别药物的生化效应，而且能够以剂量依赖的方式区分不同的化合物。(C) 2001爱思唯尔科学爱尔兰有限公司版权所有。
The clinical significance and the effects of pharmacological treatment of patients with Alzheimer's disease (AD) were evaluated by measurement of acetylcholinesterase (AChE) in the cerebrospinal fluid (CSF). CSF-AChE of AD patients was lower, not significantly, compared with controls. However, CSF-AChE was significantly increased after treatment of AD patients with AChE inhibitors (donepezil and galantamine). The increase was higher in patients treated with donezepil than in those treated with galantamine, which might be related to different mechanisms for the substances. The increase was also dose-dependent, and was especially marked in patients showing a clinical response. These data suggest that CSF biomarkers are capable not only of identifying a biochemical effect of drugs, but also of differentiating between different compounds in a dose-dependent manner. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.